Fig. 3From: Toremifene, a selective estrogen receptor modulator, significantly improved biochemical recurrence in bone metastatic prostate cancer: a randomized controlled phase II a trialPSA relapse-free survival rates in men with TOPADT, RAPADT and ADT alone (n = 15). The PSA relapse-free survival rate in men treated with TOPADT was significantly greater than in men treated with ADT alone (p = 0.04)Back to article page